CHRM2 and diabetes mellitus: The changes in M2 muscarinic receptors in the different stages of DM could have modified urothelial cholinergic autocrine signaling and interrupted barrier function, which could have caused the various therapeutic outcomes found in the clinical studies, regardless of antimuscarinic or onabotulinumtoxinA treatment.